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Introduction
Novel experimental approaches to bladder cancer have been identified, which may potentially improve the outcome of affected patients; however, investigations in humans are limited due to technical and ethical considerations [1] . Therefore, alternative animal models are desirable for bladder cancer research [2] . Currently, there are four major murine bladder 2 /2. The mice were sacrificed at the end of the 8 th week, and the tumors were excised for macroscopic examination, a real-time PCR and immunohistochemical (IHC) study.
Assessment of human PBL engraftment
Determination of human immunoglobulin levels in mice. Serum samples from individual mice were screened for the presence of human immunoglobulins (HuIg) using a commercial ELISA kit (MultiSciences Biotech, Hangzhou, China), and the whole process was performed according to the manufacturer's instructions.
Assessment of T lymphocyte invasion in mice.
Real-time PCR: After the mice were sacrificed, total RNA was isolated from RBC-depleted peripheral blood, the spleen and xenograft tissues by employing the Invitrogen RNA extraction kit. The RNA was quantified subsequently with spectrophotometry. The firststrand complementary DNA was synthesized from 500 ng of total RNA, and quantitative PCR measurements were performed with TBP as a passive reference using the Rotor-Gene system. The conditions for PCR were recorded as follows: 2 min at 50° and 10 min at 95° for one cycle followed by 10 seconds at 95° and 30 seconds at 60° for 50 cycles. The sequences of the endpoint primers for the human T lymphocyte CD3 marker were recorded as follows: forward: 5'-TCC TTG CTG TTG GGG TCTAC-3'; reverse: 5'-GGT CAT TGG GCA ACA GAGTC-3', and the sequences of the TBP primers were logged as follows: forward: 5'-TTC GGA GAG TTC TGG GATT-3'; reverse: 5'-GAA AAT CAG TGC CGT GGTTC-3'. Only one single product of approximate 100 bp was detected during the melting curve analysis following qRT-PCR (Fig. 2B, 2C ), indicating that the amplified product specifically corresponded to human CD3 mRNA. The REST-2009 program was used to calculate the relative changes in human CD3 mRNA compared with the housekeeping gene (TBP) [21] .
Immunohistochemical staining: The remaining tissues of the spleen and xenograft tissues were fixed in 4% formalin and paraffin embedded after proper processing. Sections were cut, and the tissues were deparaffinized with xylol and ethanol. Antigen retrieval was performed by using heat application in citrate buffer. The slices were blocked with 1% FCS and incubated overnight at 4°C with MAbs against human CD3. On the following day, antibody binding was revealed using the ABC Kit, and the color further developed with a DAB kit (KeyGen Biotech, Nanjing, China). The slides were counterstained with hematoxylin and eosin (H&E), and photographs were taken under standard light microscopy.
Flow cytometry: Blood was drawn weekly for the first 6 weeks after engraftment. Single cell suspensions were prepared and incubated with hypotonic saline prior to flow cytometry. After being labeled with an antibody specific for human cell surface antigen CD3 at 4° for 20 min, the cells were analyzed by using flow cytometry equipped with Cell Queste software. An irrelevant isotype-matched antibody was used as a negative control in each labeling experiment. Expression was quantified by means of comparison with control staining of matched samples.
Functional analysis of human PBL engraftment CCK-8.
To evaluate the proliferation profile of human lymphocytes in the model mice, the assay was performed with a cell counting kit 8 (CCK-8, Dojindo, Kumamoto, Japan). RBC-depleted PBLs isolated from the mice in model group were aliquoted briefly into 96-well plates in 10% FBS medium supplemented with 20 μg/ml phytohemagglutinin (PHA). Medium + 20 μg/ml PHA and PBLs incubated without PHA were used as blank and negative control wells, respectively, whereas human PBLs from healthy donors served as a positive control group. After 72 h incubation, 10 ml CCK-8 solution was added to each well, and incubation lasted for 4 more hours. The absorbance was measured with a microplate reader at the wavelength of 450 nm. Cell proliferation was reported as the proliferation index (PI), where PI = absorbance value in the experimental wells / absorbance value in the control wells.
ELISA. To evaluate cytokine released by human lymphocytes in the model mice, culture supernatants were collected after stimulation with PHA and centrifuged once to remove particulate material. Interleukin-2 5 cells per well in six-well plates with BIU-87 cells prelabeled with 1 mM CFSE. After 72 h, the BIU-87 cells were harvested from cultures and washed in PBS. The cells were then resuspended in binding buffer containing 20 mg/ml 7-AAD and incubated in the dark at 4° for 20 min. Acquisition was analyzed immediately by using flow cytometry as described previously [22] .
Statistical analysis
All in vitro experiments were performed in triplicate, and the experiments were repeated at least three times. Numerical data were presented as the mean ± SD, and a statistical analysis was performed with Student's t test or a one-way ANOVA followed by Dunnett's multiple comparison as appropriate. A two-way ANOVA followed by Tukey's test was also used to determine the significance of differences in the growth of xenografts and human PBL engraftment in mice. Statistical comparisons were performed using R-2.14.1 for Windows (www.r-project.org). A P value of less than 0.05 was considered significant.
Results

Establishment of human bladder cancer xenografts
BIU-87 is a cell line derived from human transitional cell carcinoma (TCC) initially prepared at Peking University in China [23] . It has been widely used in studies both in vitro and in vivo in China (i.e. xenograft development) [24, 25] . Using techniques hitherto developed, xenografts in SCID mice were established by subcutaneous xenotransplantation with these cells.
The general aspects of the mice, i.e., health status, average weight and fur status, were observed daily, and the results did not differ among the four groups. As the humanized mice were chimeras, they were significantly more susceptible to GVHD. However, having engrafted with PBLs of less than 5 × 10 7 /mouse, we had no GVHD or unexpected deaths observed before sacrifice in all 24 mice.
The tumor volume between the xenograft control group and model group after plantation was measured by means of ultrasound. At the time of sacrifice, no xenografts developed in humanized or blank control mice. In contrast, all mice from xenograft control and model groups developed tumors (Fig. 1A, D ), which were further investigated through macroscopic histology staining. Because no specific immunohistological antibodies were available for the cell line we used, here we provided only the representative histological photograph with HE staining. (Fig. 1C, F) Approximately 6-7 days after xenotransplantation, tumors were detectable under ultrasound in xenograft control animals. The mean tumor volume of 2490.8 ± 310.0 mm 3 within 6 weeks of the initial appearance was recorded (Fig. 1A, B) . Interestingly, the model animals showed much slower rates of tumor growth with significantly smaller volumes at the time of sacrifice (1116.3 ± 150.1 mm 3 , Fig. 1D , E, p＜0.05).
Human PBL engraftment in model mice: Serum from the model mice contained T and B lymphocytes
To evaluate the possible engraftment of T and B lymphocytes, serum samples from individual mice were monitored for the presence of HuIg and human CD3 mRNA after sacrifice. Consistent with a previous report [14] , all humanized animals produced detectable levels of HuIg. The model mice had mean serum HuIg levels in excess of 500 μg/ml, which were significantly higher than that in the humanized control mice (P<0.005). Animals without PBLs, including the blank and xenograft control mice, did not produce detectable levels of HuIg ( Fig. 2A) .
Moreover, quantification of serum CD3 mRNA revealed positive expression in the serum of model and humanized control mice, but not in that of blank or xenograft control ones ( 
Human PBL engraftment in model mice: T lymphocytes infiltrated into the spleens of the model mice
To characterize the T lymphocyte population in the spleens, the tissues were weighed, and real-time PCR and immunohistochemical staining were performed to analyze CD3 mRNA and protein in all individuals. Consequently, the weight of spleen in the xenograft control mice was approximately 50 mg, which was slightly higher than that in the blank control mice but still significantly lower than those in the humanized control and model mice (Fig. 3A-E) . Similarly, human CD3 mRNA and CD3 + cells were detectable by using qRT-PCR and IHC staining in the humanized control and model mice, but not in the blank and xenograft control mice (Fig. 3F-J) , suggesting the presence of T lymphocyte infiltration into the spleen of the model mice. Interestingly, no significant correlation between the spleen weight and the level of the CD3 mRNA was identified between the humanized control mice and the model ones ( Fig. 3E-F) .
Human PBL engraftment in model mice: T lymphocytes penetrated into the model mice xenografts
Because the above data suggested the infiltration of T lymphocytes into serum and spleens of the model mice, the potency of penetration into the xenograft was further indicates the growth curve after quantification. Statistical analysis was performed using two-way ANOVA followed by Tukey's test, and the difference between the xenograft control and model mice was significant (p﹤0.05). examined after sacrifice. In contrast to the control xenograft mice, despite the presence of human CD3 mRNA in the model mice, IHC staining for CD3 was also positive in these xenograft tissues at a later point of time ( Fig. 4A-E) . This provided evidence that a number of human T lymphocytes had penetrated into the xenografts in the model mice.
Detailed development of human PBL engraftment in the model mice
Although these results primarily demonstrated the successful establishment of a BIU-87 xenograft in humanized SCID mice, the detailed development of human PBLs in mice was unknown during the 6-week engraftment. Therefore, we quantified the HuIg and CD3 + cell contents in peripheral blood taken in advance weekly from the mice during the 6-week engraftment by means of ELISA assays and flow cytometry. The model mice had substantial levels (≥100 μg/ml) of HuIg in their sera one week after PBL inoculation, and the changes were expressed as a gradually increasing trend corresponding to the inoculation time. The humanized control mice, on the other hand, did not start to have the same amount of HuIg until much later, i.e., 3-4 weeks after PBL inoculation. Among blank and xenograft control mice, however, no HuIg was detected at any of the five time intervals (Fig. 5A) .
The engraftment of CD3 + cells was relatively poor during the initial 3 weeks after transplantation (Fig. 5B) . Unexpectedly, as the inoculation continued, the content of T shows the relative expression of serum CD3 mRNA in mice. Statistical analysis was performed by one-way ANOVA followed by Dunnett's multiple comparison. The model mice produced significantly higher levels of serum HuIg (P<0.05), but they did not show higher CD3 mRNA expression (P ≥ 0.05) than the humanized control mice. Meanwhile, the blank and xenograft control mice did not show any HuIg and CD3 mRNA after sacrifice.
Cell Physiol
lymphocytes in the serum from the model mice increased to nearly 20% at 6 weeks, which is slightly higher than that in the humanized control mice (P ≥ 0.05). In the blank and xenograft control mice, again, there were no CD3 + cells detected at any time before sacrifice (Fig. 5B) . Overall, it can be concluded that both T and B lymphocytes developed differently after PBL engraftment in model mice.
Function of human lymphocytes in model mice
As reported in the existing literature, a variety of assays have been employed to assess lymphocyte functions. It was of great interest to us to be able to determine the extent of lymphocyte proliferation in the current study. Therefore, the complementary approach of CCK8 assay was carried out. As shown in Fig. 6A , the proliferation profile of human lymphocytes in the serum of the model mice was comparable to that in healthy donors after PHA boosting (P ≥ 0.05), indicating that these human lymphocytes can be stimulated to proliferate in response to PHA.
Considering that there has been no evidence showing that BIU-87 secretes any human IL-2, an IL-2 release experiment was performed using culture supernatants from the above experiments instead of using the model mice serum. Unexpectedly, the lymphocyte's ability to release cytokines was impaired (as shown in Fig. 6B ), as the level of human IL2 in the model mice was significantly lower than that in healthy donors. It was also of interest to examine the function of these cells by measuring in vitro lysis of sensitive targets. Since BIU-87 cells are sensitive to human lymphocytes [22] , these cells were used in the present experiments. Consequently, human lymphocytes from the model mice displayed a lysis response of BIU-87 at levels similar to that of normal human PBLs (mean rate of lysis with 4.8% vs. 6.1% (as shown in Fig. 6C-E) .
Discussion
Although bladder cancer greatly affects patients' well-being [26] , its intricate biology is poorly understood. New therapeutics targeting at bladder cancer are emerging [27] ; however, their progress is hindered by limitations in the scope of in vitro experimentation. Therefore, there has been a growing demand for animal models that are able to sustain studies of bladder cancer in vivo [2] .
In theory, an ideal tumor model should allow tumors to grow in locus, but in practice, orthotopic models for bladder cancer are severely restricted by technical difficulties. The procedures to produce such models are time-consuming and tumor uptake is often poor [28] . Among the existing orthotopic models, pretreatment with poly-L-lysine and trypsinoptimized orthotopic bladder tumor implantation is required to improve bladder tumor uptake [29] . Unexpectedly, the tumor size is still extremely limited due to the small murine bladder capacity [29, 30] . 
Cellular Physiology and Biochemistry
Though failing to provide an organ-specific tumor microenvironment, subcutaneous models have been widely used, because they facilitate tumor treatments, monitoring and generate good tumor size [30] . In this study, we chose to use the subcutaneous xenograft to investigate the bladder cancer model we established.
To develop a subcutaneous xenograft, immunodeficient nude mice are commonly used, thereby leading to a major disadvantage of a deficient immune response in these models. Compared to nude mice, SCID mice are profoundly lacking in functional, mature T and B lymphocytes, and are more suitable for xenotransplantation [31] . Moreover, they are suitable hosts for the engraftment of human immunocompetent cells (humanized SCID mouse) [9] [10] [11] [12] [13] , resulting in a somewhat more relevant microenvironment [30] . These animals not only are ready to accept grafts of human immunocompetent cells to develop humanized SCID mice, but they are also able to host malignant human tumors to develop subcutaneous xenografts. As such, if the engraftment of these two functionally varied cell types to the same animal is successful, it would be possible for us to develop an in vivo chimera model. In particular, this model is able to overcome the immunodeficiency issues of the other models using nude mice xenograft [14] [15] [16] .
In fact, the success of engrafting human PBLs into SCID mice has been varied in different laboratory reports [32] , which may be attributed to a range of factors, such as graft issues and host situations. In this context, a series of potential factors were considered in our study.
For example, C.B.17 SCID mice contain innate immune cells, i.e., undeleted natural killer (NK) cells [8, 33] , and these may present a problematic barrier to immunocompetent grafts. To overcome this barrier, the reduction of interference by the NK cells is extremely desirable. To date, there have been multiple published data demonstrating that the pretreatment similar to what we used could achieve significant efficiency of engraftment. For example, + cell contents (B) were quantified by ELISA assay and flow cytometry, respectively. Statistical analysis was performed by two-way ANOVA followed by Tukey's test, and the difference of HuIg levels between controls and model was significant (No difference in the CD3+ cell content between the humanized control and model was found.
and minimizing the possibility of GVHD. Consequently, no GVHD was observed in any of the animals in our study.
The cluster of differentiation (CD) is commonly used as cell markers in immunophenotyping. Although CD4 and CD8 are commonly used as markers for assessing helper and cytotoxic T cells respectively, these molecules are defined in combination with CD3+ (i.e. T helper cell markers are CD45+, CD3+, CD4+; Cytotoxic T cell markers are CD45+, CD3+, CD8+) [37] . Many researchers have chosen CD3 as the cell marker for the T lymphocyte detection [38] . For example, anti-CD3 monoclonal primary antibody was used for T-lymphocyte detection in the recent two studies with good sensitivity in measurement [39, 40] . Hence, we decided to choose CD3 as a marker for the T lymphocytes infiltration.
Consequently, HuIg and human CD3 mRNA, protein were only detected in the humanized mice (including the model mice and the humanized control mice, as shown in Fig. 2A-D) . We observed that the HuIg concentrations were a bit lower in humanized control mice than that in model mice (p＜0.05). Meanwhile, CD3 mRNA expression of humanized control mice was comparable with that of the model mice. We believed that the serum infiltration of human T and B cells was possibly different between the groups (humanized control vs model).
In general, a large number of different types of functional immune cells are located in the spleen. Therefore, we examined the existence of human PBLs in the spleen to further evaluate our establishment of the engraftment. We again found the enlargement of the spleen, and the human CD3 mRNA and molecular markers were detected in the humanized mice, especially in the model mice (Fig. 3A-J) . These experiments clearly demonstrated that the spleens of the model mice were successfully engrafted with human PBLs.
These results represent our successful establishment of a novel xenograft model of human bladder cancer with BIU-87 cells in the humanized mice. Their tumor growth exhibited a characteristic pattern. However, the penetration of the engrafted PBLs into the subcutaneous xenograft has not been explored in the previous studies of the humanized SCID mouse models bearing subcutaneous tumors. We then investigated the possibility of eliciting a specific immune response to growing tumors within these animals. For the first time, we discovered that transplanted PBLs penetrated into the subcutaneous xenografts, as human CD3 mRNA and CD3-positive cells were both detected in these xenografts (Fig. 4A-E) .
We hope that not only the human lymphocytes were engrafted into the tumor xenograft of model mice, but their functions were also fully preserved, if this model is to be used in studies of cancer immunotherapy. Because it has been shown that several cytokines, such as IL-4, IL-5, IL-2, IFN-γ, were detectable in SCID mice transplanted with human PBLs [41] , we only included IL-2 as the representative cytokine in the current study. We found that the isolated PBLs from the serum of model mice did produce certain cytokines, i.e., IL-2 ( Fig.  6B ) and they also maintained the proliferating profile (Fig. 6A) , representing the underlying immune responses were retained.
Because these cells, together with the cytokines produced, may be responsible for the inhibition of xenograft growth, we tested their cytotoxicity against TCC BIU-87 cells. The results showed that similar to PBLs from healthy donors, these PBLs also reacted to the xenograft BIU-87 cells and contributed to their lysis ( Fig. 6C-E) . Therefore, it is more likely that the functions of PBLs transplanted into model mice were preserved to a certain extent.
Iwanuma et al. [42] have confirmed that by s.c. coengraftment of PBLs and tumor into SCID mice, PBLs suppress the growth of tumor xenograft; and the tumor suppression was dependent upon T lymphocytes. Sabzevari H et al. [43] demonstrated that when engrafted with T lymphocytes, SCID mice bearing tumors showed a significant reduction of metastasis in the number of foci and in the lymph nodes. Liu et al. [6] found the xenograft growth in SCID mice was significantly inhibited by intraperitoneal injection of PBMCs. So they concluded that "PBMC transplantation inhibits lung carcinoma progression via the reconstitution of the immune system, particularly of cytotoxic T lymphocytes."
In our study, we first showed: ①the model mice had high levels of HuIg and human PBL T cells infiltration and ②the xenografts growth was inhibited (Fig. 1G) . These results provided the initial evidence of the potential occurrence of immunity-mediated tumor suppression. Additionally, we showed that transplanted PBLs penetrated into the xenografts of the model mice ( Fig. 4A-E) . These results provided a second level of evidence demonstrating the underlying interaction between the subcutaneous tumor and the reconstructed immune system in model mice. Finally, we showed that the PBLs infiltrated into the xenograft and maintained their function (Fig. 6A-E) , thus offering further evidence for the possible tumor suppression of humanized immune response in model mice.
In view of the above observations, we hypothesize that reduced tumor size in model group implies that engrafted lymphocytes may either inhibit the proliferation of tumor cells or induce their apoptosis. Nonetheless, so far we have no specific evidence verifying this hypothesis. Therefore, further study needs to be done. Our major goal in this study was to successfully establish and validate this model as a useful approach in cancer immunology studies, esp. to bladder cancer. However, similar to some of the related studies [6, [14] [15] [16] , this study did not include any T cell functions comparison between the humanized control group and the model group. Yet, we strongly believe that it would be of great significance to our future studies to explore the possibility of interaction between the immune system and the tumors using this model.
The role of the secretary system in lymphocytes has been investigated in details in anticancer research [44] . However, it became apparent in our study that the mean secretary viability of the transplanted lymphocytes in the model mice was significantly lower than that from healthy donors. This could have resulted from the fact that the immune cells of the mice, such as NK cells, had an inhibitory influence on the viability of the transplanted PBLs in these animals. Recently, the generation of a new immunodeficient host (NOD-scid Il2ry null mice) has achieved higher levels of PBL engraftment via usual routes, providing potential for overcoming many of the existing limitations in current humanized SCID mice [45] . Therefore, new investigations into more cases seem to be necessary to verify the secretory viability of transplanted lymphocytes within NOD-scid Il2ry null mice. In conclusion, we have generated a novel subcutaneous xenograft model of bladder cancer in humanized C.B.17 SCID mice. This study provides a promising model for further investigations into the human immune responses and for evaluating the immunotherapeutic approaches in vivo in this type of bladder cancer.
